

reflect the changes in sponsor name and address.

FDA has determined under 21 CFR 25.33(a)(1) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

**List of Subjects**

**21 CFR Part 510**

Administrative practice and procedure, Animal drugs, Labeling, Reporting and recordkeeping requirements.

**21 CFR Part 522**

Animal drugs. Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 510 and 522 are amended as follows:

**PART 510—NEW ANIMAL DRUGS**

1. The authority citation for 21 CFR part 510 continues to read as follows:

**Authority:** 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.

**§ 510.600 [Amended]**

2. Section 510.600 *Names, addresses, and drug labeler codes of sponsors of approved applications* is amended in the table in paragraph (c)(1) in the entry "Anika Research, Inc." and in paragraph (c)(2) in the entry "060865" by removing the sponsor name and address and inserting in its place "Anika Therapeutics Inc., 236 West Cummings Park, Woburn, MA 01801".

**PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS**

3. The authority citation for 21 CFR part 522 continues to read as follows:

**Authority:** 21 U.S.C. 360b.

4. Section 522.1145 is amended by revising paragraph (a)(2) and adding paragraph (f) to read as follows:

**§ 522.1145 Hyaluronate sodium injection.**

(a) \* \* \*

(2) *Sponsor.* See 000009 in § 510.600(c).

\* \* \* \* \*

(f)(1) *Specifications.* Each milliliter of sterile aqueous solution contains 11 milligrams of hyaluronate sodium.

(2) *Sponsor.* See 060865 in § 510.600(c).

(3) *Conditions of use*—(i) *Amount.* Small and medium-size joints (carpal, fetlock)—22 milligrams; larger joint (hock)—44 milligrams.

(ii) *Indications for use.* Treatment of joint dysfunction in horses due to noninfectious synovitis associated with equine osteoarthritis.

(iii) *Limitations.* For intra-articular injection in horses only. Treatment may be repeated at weekly intervals for a total of three treatments. Not for use in horses intended for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Dated: October 25, 1998.

**Margaret Ann Miller,**

*Acting Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.*

[FR Doc. 98-29332 Filed 11-2-98; 8:45 am]

BILLING CODE 4160-01-F11

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration**

**21 CFR Part 558**

**New Animal Drugs for Use in Animal Feeds; Carbadox**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Final rule.

**SUMMARY:** The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a supplemental new animal drug application (NADA) filed by Pfizer Animal Health, Inc. The supplemental NADA provides for the establishment of a 42-day slaughter withdrawal period for use of carbadox in swine feed.

**EFFECTIVE DATE:** November 3, 1998.

**FOR FURTHER INFORMATION CONTACT:**

William T. Flynn, Center for Veterinary Medicine (HFV-133), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-594-1652.

**SUPPLEMENTARY INFORMATION:** Pfizer, Inc., 235 East 42d St., New York, NY 10017, is sponsor of NADA 41-061 that provides for the use of Mecadox® 10 (carbadox) Type A medicated article used to make Type B and Type C medicated swine feeds. Mecadox® is indicated for the control of bacterial swine enteritis, increased rate of weight gain, and improved feed efficiency. The sponsor filed a supplemental NADA that provides for the establishment of a withdrawal period of 42 days in swine and a limitation against use in pregnant swine or swine intended for breeding purposes. The supplemental NADA is approved as of October 5, 1998, and the

regulations are amended in 21 CFR 558.115(d)(1)(ii) and (d)(2)(ii) to reflect the approval. The basis for approval is discussed in the freedom of information summary.

In accordance with the freedom of information provisions of 21 CFR part 20 and 514.11(e)(2)(ii), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.

The agency has determined under 21 CFR 25.33(a)(1) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

**List of Subjects in 21 CFR Part 558**

Animal drugs, Animal feeds.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under the authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 558 is amended as follows:

**PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS**

1. The authority citation for 21 CFR part 558 continues to read as follows:

**Authority:** 21 U.S.C. 360b, 371.

2. Section 558.115 is amended by revising paragraphs (d)(1)(ii) and (d)(2)(ii) to read as follows:

**§ 558.115 Carbadox.**

\* \* \* \* \*

(d) \* \* \*

(1) \* \* \*

(ii) *Limitations.* Not for use in pregnant swine or swine intended for breeding purposes. Do not feed to swine within 42 days of slaughter.

(2) \* \* \*

(ii) *Limitations.* Not for use in pregnant swine or swine intended for breeding purposes. Do not feed to swine within 42 days of slaughter.

\* \* \* \* \*

Dated: October 25, 1998.

**Margaret Ann Miller,**

*Acting Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.*

[FR Doc. 98-29334 Filed 11-2-98; 8:45 am]

BILLING CODE 4160-01-F